129 related articles for article (PubMed ID: 21193836)
1. Selection of peptides binding to HCV e2 and inhibiting viral infectivity.
Hong HW; Lee SW; Myung H
J Microbiol Biotechnol; 2010 Dec; 20(12):1769-71. PubMed ID: 21193836
[TBL] [Abstract][Full Text] [Related]
2. Identification of peptides that bind hepatitis C virus envelope protein E2 and inhibit viral cellular entry from a phage-display peptide library.
Lü X; Yao M; Zhang JM; Yang J; Lei YF; Huang XJ; Jia ZS; Ma L; Lan HY; Xu ZK; Yin W
Int J Mol Med; 2014 May; 33(5):1312-8. PubMed ID: 24573486
[TBL] [Abstract][Full Text] [Related]
3. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry.
Liu R; Tewari M; Kong R; Zhang R; Ingravallo P; Ralston R
Antiviral Res; 2010 May; 86(2):172-9. PubMed ID: 20156485
[TBL] [Abstract][Full Text] [Related]
4. Selection and target-site mapping of peptides inhibiting HCV NS5B polymerase using phage display.
Kim MS; Park C; Lee JH; Myung H
J Microbiol Biotechnol; 2008 Feb; 18(2):328-33. PubMed ID: 18309279
[TBL] [Abstract][Full Text] [Related]
5. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticosteroids increase cell entry by hepatitis C virus.
Ciesek S; Steinmann E; Iken M; Ott M; Helfritz FA; Wappler I; Manns MP; Wedemeyer H; Pietschmann T
Gastroenterology; 2010 May; 138(5):1875-84. PubMed ID: 20152835
[TBL] [Abstract][Full Text] [Related]
7. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus.
Chen C; Qiu H; Gong J; Liu Q; Xiao H; Chen XW; Sun BL; Yang RG
Arch Virol; 2012 Jul; 157(7):1301-12. PubMed ID: 22491814
[TBL] [Abstract][Full Text] [Related]
8. The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity.
McCaffrey K; Gouklani H; Boo I; Poumbourios P; Drummer HE
J Gen Virol; 2011 Jan; 92(Pt 1):112-21. PubMed ID: 20926639
[TBL] [Abstract][Full Text] [Related]
9. A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.
Yin P; Zhang L; Ye F; Deng Y; Lu S; Li YP; Zhang L; Tan W
Sci Rep; 2017 Jun; 7(1):3976. PubMed ID: 28638089
[TBL] [Abstract][Full Text] [Related]
10. A new natural α-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV.
Yan R; Zhao Z; He Y; Wu L; Cai D; Hong W; Wu Y; Cao Z; Zheng C; Li W
Peptides; 2011 Jan; 32(1):11-9. PubMed ID: 20950663
[TBL] [Abstract][Full Text] [Related]
11. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
12. Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes.
Abe K; Nozaki A; Tamura K; Ikeda M; Naka K; Dansako H; Hoshino HO; Tanaka K; Kato N
Microbiol Immunol; 2007; 51(1):117-25. PubMed ID: 17237607
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
14. Mouse monoclonal antibody towards e1 specific epitope blocks viral entry and intracellular viral replication in vitro.
Tabll AA; Moustafa RI; El Abd YS; Bader El Din NG; El-Shenawy R; Yousef H; Hussein M; Dawood RM; Omran MH; El-Awady MK
J Immunoassay Immunochem; 2014; 35(1):60-73. PubMed ID: 24063617
[TBL] [Abstract][Full Text] [Related]
15. Selection of a phage-displayed peptide recognized by monoclonal antibody directed blocking the site of hepatitis C virus E2 for human CD81.
Cao J; Liao XL; Wu SM; Zhao P; Zhao LJ; Wu WB; Qi ZT
J Microbiol Methods; 2007 Mar; 68(3):601-4. PubMed ID: 17178166
[TBL] [Abstract][Full Text] [Related]
16. Synthesized peptide 710-725 from HCV subtype 1a E2 glycoprotein blocks HCV infection through competitive binding of CD81.
Liu X; Chen N; Lin S; Liu M
Int J Mol Med; 2016 Mar; 37(3):836-42. PubMed ID: 26796693
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.
Murao K; Imachi H; Yu X; Cao WM; Nishiuchi T; Chen K; Li J; Ahmed RA; Wong NC; Ishida T
Gut; 2008 May; 57(5):664-71. PubMed ID: 17998316
[TBL] [Abstract][Full Text] [Related]
18. Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.
Chen F; Zhao Y; Liu M; Li D; Wu H; Chen H; Zhu Y; Luo F; Zhong J; Zhou Y; Qi Z; Zhang XL
Antimicrob Agents Chemother; 2010 Aug; 54(8):3355-64. PubMed ID: 20479194
[TBL] [Abstract][Full Text] [Related]
19. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles.
Tao W; Xu C; Ding Q; Li R; Xiang Y; Chung J; Zhong J
Virology; 2009 Dec; 395(1):67-76. PubMed ID: 19793603
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors.
Ziegler S; Kronenberger B; Albrecht BA; Kaul A; Gamer AL; Klein CD; Hartmann RW
J Biomol Screen; 2009 Jul; 14(6):620-6. PubMed ID: 19531666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
